共 45 条
- [1] Sequential ipilimumab (Ipi) versus best supportive care (BSC) following first-line chemotherapy (Ctx) in patients (pts) with unresectable locally advanced or metastatic gastric or gastro-esophageal junction (GEJ) cancer: A randomized, open-label, two-arm, phase II trial (CA184-162) of immunotherapy as a maintenance conceptJOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Moehler, Markus HermannKim, Yeul HongTan, Iain B.Balogh, AgnesSanchez, Teresa KongBang, Yung-Jue
- [2] Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish).JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS484 - TPS484Lee, Keun-WookMoehler, Markus H.Cunningham, DavidWainberg, Zev A.Uronis, Hope ElizabethOh, Do-YounKim, In-HoShim, Byoung YongSym, Sun JinAltura, Rachel A.Stilian, Melissa C.Parker, Elizabeth C.Klempner, Samuel J.
- [3] REGARD: A phase III, randomized, double-blind trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line pCANCER RESEARCH, 2013, 73 (08)Fuchs, Charles S.Tomasek, JiriCho, Jae YongFilip, DumitruPassalacqua, RodolfoGoswami, ChancalSafran, HowardDos Santos, Lucas VieiraAprile, GiuseppeFerry, DavidMelichar, BohuslavTehfe, MoustaphaTopuzov, EldarTabernero, JosepRaymond Zalcberg, JohnChau, IanKoshiji, MinoriHsu, YanzhiSchwartz, JonathanAjani, Jaffer
- [4] A phase III trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Xu, Rui-huaArkenau, Hendrik-TobiasBang, Yung-JueDenlinger, Crystal S.Kato, KenTabernero, JosepWang, JinLi, JiangCastro, HenryMoehler, Markus Hermann
- [5] Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)Janjigian, Yelena YuriyAdenis, AntoineAucoin, Jean-SebastienBarone, CarloBoku, NarikazuChau, Ian
- [6] A phase Ill, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)Galsky, Matt D.Necchi, AndreaSridhar, Srikala S.Ogawa, OsamuRuscica, DarioAngra, NatashaBellmunt, Joaquim
- [7] CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) plus ipilimumab (IPI) or nivo plus chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)Moehler, Markus H.Janjigian, Yelena YuriyAdenis, AntoineAucoin, Jean-SebastienBoku, NarikazuChau, IanCleary, James M.Feeney, KynanFranke, Fabio A.Mendez, Guillermo ArielSchenker, MichaelLi, MingshunHitre, ErikaCouture, FelixKaramouzis, MichalisEtienne, Pierre-LucAjani, Jaffer A.
- [8] Safety and efficacy results from the phase I/IIa study of FG-M108 plus CAPOX as first-line (1L) treatment for patients with CLDN18.2+/HER2-locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinomaJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Liu, FunanGong, JifangJin, ZhaoyuZhang, MiaoZhang, ShuZhang, YanqiaoLiang, XinjunLi, YunYang, XiaochunYang, YapingShen, Lin
- [9] A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in combination with tremelimumab and SOC chemotherapy versus SOC chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Galsky, Matt D.Necchi, AndreaSridhar, Srikala S.Ogawa, OsamuAngra, NatashaHois, StephanHe, PhilipGhiorghiu, Dana C.Bellmunt, Joaquim
- [10] JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1 antibody) maintenance therapy vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancerANNALS OF ONCOLOGY, 2016, 27 : 81 - 82Julien, TaiebMaria, Di BartolomeoAntonio, CubilloJayne, GurtlerDeborah, WilburXiong HuilingJenny, ZhangJean-Marie, CuillerotNarikazu, BokuMarkus, Moehler